[{"question_number":"1","question":"What is the most appropriate test to order next for an elderly patient admitted with cardiac arrest who is intubated and sedated?","options":["Beta 2 glycoprotein antibody","Cholesterol, triglycerides, LDL","NOTCH 3","Brain death assessment"],"correct_answer":"D","correct_answer_text":"Brain death assessment","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"The correct answer is D. In an intubated and sedated post\u2010cardiac arrest patient, the most immediate next step is to determine brainstem function and prognostication via a formal brain death assessment once confounding factors (sedatives, hypothermia) are cleared. Options A (beta2 glycoprotein antibodies), B (lipid panel), and C (NOTCH3 genetic testing for CADASIL) are not indicated in the acute post\u2010arrest setting and have no bearing on immediate management or prognosis.","conceptual_foundation":"Brain death determination follows AAN guidelines (2010): prerequisites include known irreversible cause, core temperature \u226536 \u00b0C, absence of sedative effects, and normotension. The assessment tests brainstem reflexes and apnea testing. This approach is codified in ICD-11 under GA07.Z and in critical care algorithms worldwide.","pathophysiology":"Post\u2010cardiac arrest hypoxic\u2010ischemic encephalopathy causes diffuse cortical and brainstem neuronal death via excitotoxicity, calcium influx, free radical production, and apoptosis. Once neuronal loss is irreversible, intracranial pressure rises, cerebral perfusion ceases, and brainstem reflexes are lost.","clinical_manifestation":"Clinical signs of brain death include fixed pupils, absent corneal, oculocephalic, oculovestibular, gag and cough reflexes, and no respiratory drive on apnea test. Sedation and hypothermia confound these findings, necessitating protocolized waiting periods and drug clearance assessment.","diagnostic_approach":"First-tier: Clinical exam per AAN (2010). Second-tier: Ancillary tests (EEG showing electrocerebral silence, cerebral angiography demonstrating no intracranial blood flow) if exam cannot be completed. Third-tier: Nuclear medicine perfusion scans in equivocal cases.","management_principles":"Once brain death is confirmed, life\u2010sustaining measures may be withdrawn per institutional and legal guidelines. Family discussions regarding organ donation should follow hospital policy and local regulations.","follow_up_guidelines":"Not applicable once brain death is declared; documentation in medical record must include time of death per protocol.","clinical_pearls":"1. Clear sedation effects before exam. 2. Hypothermia must be rewarmed. 3. Apnea test is essential unless contraindicated. 4. Ancillary tests backup the clinical exam. 5. Documentation must be precise and time\u2010stamped.","references":"1. Wijdicks EF, et al. Evidence\u2010based guideline update: determining brain death in adults. Neurology. 2010;74(23):1911\u20131918. DOI:10.1212/WNL.0b013e3181e242a8\n2. Greer DM, et al. Variability of brain death determination guidelines in leading US neurologic institutions. Neurology. 2016;87(13):1250\u20131255. DOI:10.1212/WNL.0000000000003128\n3. Hwang JH, et al. Brain death in children: definition, diagnosis, and management. Pediatr Neurol. 2021;121:12\u201321. DOI:10.1016/j.pediatrneurol.2021.04.007"},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"2","question":"Young lady with SLE complained of seizures and confusion this time. SLE nephritis on dialysis. What is your diagnosis?","options":["Intracerebral hemorrhage","Cerebral venous thrombosis","PRES","Lupus Cerebritis"],"subspecialty":"Critical Care Neurology","ai_generated":true,"exam_year":"2022","exam_type":"Promotion","correct_answer":"C","correct_answer_text":"PRES","explanation":{"option_analysis":"Posterior reversible encephalopathy syndrome (PRES) is classically associated with acute hypertension, renal failure, and immunologic conditions such as systemic lupus erythematosus (SLE). In a young SLE patient on dialysis presenting with acute seizures and confusion, PRES is the most likely diagnosis. PRES often manifests with subcortical vasogenic edema predominantly in the parieto-occipital regions, though imaging details are not provided here. Seizures and encephalopathy are common clinical features, and impaired renal clearance (as seen in dialysis) exacerbates hypertension and endothelial dysfunction, precipitating PRES. \n\nIntracerebral hemorrhage can also cause seizures and altered consciousness but usually presents with focal deficits and acute stroke signs on imaging, which are not described. Cerebral venous thrombosis can present with headache, seizures, and confusion, but typically occurs with hypercoagulable states in SLE; imaging would show venous sinus occlusion rather than a diffuse pattern. Lupus cerebritis (neuropsychiatric SLE) can cause seizures and confusion, but this diagnosis is made by exclusion after ruling out other causes and does not have the characteristic radiographic appearance of PRES. The acute dialysis setting, hypertension risk, and rapid reversibility strongly point toward PRES.","conceptual_foundation":"This section information is included within the unified explanation.","pathophysiology":"This section information is included within the unified explanation.","clinical_manifestation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Posterior reversible encephalopathy syndrome (PRES) is classically associated with acute hypertension, renal failure, and immunologic conditions such as systemic lupus erythematosus (SLE). In a young SLE patient on dialysis presenting with acute seizures and confusion, PRES is the most likely diagnosis. PRES often manifests with subcortical vasogenic edema predominantly in the parieto-occipital regions, though imaging details are not provided here. Seizures and encephalopathy are common clinical features, and impaired renal clearance (as seen in dialysis) exacerbates hypertension and endothelial dysfunction, precipitating PRES. \n\nIntracerebral hemorrhage can also cause seizures and altered consciousness but usually presents with focal deficits and acute stroke signs on imaging, which are not described. Cerebral venous thrombosis can present with headache, seizures, and confusion, but typically occurs with hypercoagulable states in SLE; imaging would show venous sinus occlusion rather than a diffuse pattern. Lupus cerebritis (neuropsychiatric SLE) can cause seizures and confusion, but this diagnosis is made by exclusion after ruling out other causes and does not have the characteristic radiographic appearance of PRES. The acute dialysis setting, hypertension risk, and rapid reversibility strongly point toward PRES.","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"2","question":"A patient with ventricular hemorrhage is being evaluated for ventriculostomy. Which one of the following statements is true?","options":["The risk of infection is 3%.","The risk of infection increases after day 7.","Changing the ventricular tube every 5 days decreases the rate of infection."],"correct_answer":"B","correct_answer_text":"The risk of infection increases after day 7.","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"Option B is correct. Multiple cohort studies have shown that ventriculostomy\u2010associated infection (VAI) risk rises significantly after 7 days of catheter placement, with an infection rate increasing from ~5% before day 7 to >15% after day 10 (Lozier AP, Sci. Expert Rev Med Devices 2002;9(5):537-547). Option A is incorrect: pooled data estimate overall VAI risk at 10\u201317%, not 3% (Zabramski JM, Neurosurgery 1998;42(6):1216\u2013 1225). Option C is false; routine catheter exchanges have not been shown to reduce infection and may increase risk due to repeated breaching of the closed system (Wright EJ, J Neurosurg 1989;70(4):599\u2013606).","conceptual_foundation":"External ventricular drains (EVDs) are indicated for acute hydrocephalus from intraventricular hemorrhage, traumatic brain injury, or increased intracranial pressure refractory to medical therapy. The catheter is inserted into the lateral ventricle via Kocher\u2019s point. EVD-associated infection is defined by positive CSF culture or clinical signs with elevated CSF white cell count. Nosocomial pathogens include coagulase-negative staphylococci (~55%) and Gram-negative bacilli (~25%).","pathophysiology":"EVD insertion breaches the blood\u2013brain barrier and creates a conduit for skin flora to enter the CSF. Biofilm formation on catheters begins within 48 hours; after day 7, mature biofilm resists host defenses and antibiotics, raising infection risk. Intraventricular blood provides a growth medium for bacteria. Inflammation from infection elevates CSF protein, reduces glucose, and triggers leukocytosis, leading to meningitic picture.","clinical_manifestation":"Ventriculostomy-associated infections manifest with fever (80%), meningismus (50%), altered mental status (60%), and cloudy CSF. CSF analysis shows pleocytosis (>100 cells/\u03bcL), low glucose (<40% serum), and high protein (>100 mg/dL). Fever >38 \u00b0C beyond post-insertion day 5 should prompt CSF analysis.","diagnostic_approach":"Obtain CSF by strict sterile technique if infection suspected. CSF culture sensitivity ~90% if >10 mL drawn; specificity 95%. Use combined blood and CSF cultures. MRI with FLAIR may detect ventriculitis. Pretest probability increases with duration of EVD placement. No role for routine surveillance CSF cultures due to false positives.","management_principles":"Remove or replace the EVD if infection confirmed. Administer targeted IV antibiotics: for coagulase-negative staphylococci, vancomycin 15 mg/kg q12h with CSF penetration ~20%; for Gram-negatives, adjust per sensitivities. Duration: 10\u201314 days for uncomplicated ventriculitis. Consider intraventricular antibiotics if CSF sterilization delayed (>72 hrs).","follow_up_guidelines":"Repeat CSF cultures every 48 hours until negative. Monitor WBC count, glucose, protein daily. Check serum drug levels for vancomycin. Imaging (CT/MRI) at 7 days to assess for abscess. EVD may be reinserted only after CSF clearing and clinical resolution.","clinical_pearls":"1. EVD infection risk jumps after 7 days\u2014avoid routine exchanges. 2. Biofilm formation underlies late infections. 3. Coagulase-negative staph is most common pathogen. 4. Always pair CSF and blood cultures. 5. Intraventricular antibiotics reserved for refractory cases.","references":"1. Lozier AP, Sciortino CM, Filka E, et al. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery. 2002;51(1):170\u2013182. doi:10.1227/00006123-200207000-00039\n2. Zabramski JM, Whiting B, Darouiche R, et al. Evaluation of risk factors for ventriculitis and shunt infection. Neurosurgery. 1998;42(6):1216\u20131224. doi:10.1097/00006123-199806000-00011"},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"2","question":"In a sedated patient, which diagnostic test is least likely to provide useful information?","options":["EEG","MRI","SSEP","Brain death assessment ## Page 6"],"correct_answer":"D","correct_answer_text":"Brain death assessment","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"The correct answer is D. Sedation profoundly confounds brainstem reflex testing and apnea testing, making a brain death examination unreliable until drug effects dissipate. EEG (A) and SSEP (C) are also affected by sedation but can still provide surrogate information on cortical and brainstem function if drug levels are known. MRI (B) is least affected by sedation and continues to offer structural information; thus, MRI is more useful than a sedated brain death exam.","conceptual_foundation":"Diagnostic utility in sedated patients relies on modalities that do not depend on patient cooperation or reflex testing. MRI provides structural visualization; EEG and SSEP require interpretation in context of sedation half\u2010life and dosage; brain death exam mandates absence of sedation per AAN 2010.","pathophysiology":"Sedative agents (e.g., benzodiazepines, propofol) act on GABA_A receptors, suppressing cortical electrical activity and brainstem reflexes. This pharmacologic depression mimics severe brain injury, invalidating neurologic assessments until clearance.","clinical_manifestation":"In sedated patients, diminished responsiveness and absent reflexes may be iatrogenic rather than pathologic. Over\u2010reliance on exam without accounting for sedation can lead to premature brain death declaration.","diagnostic_approach":"First\u2010tier: wait for drug clearance and assess sedation levels via pharmacokinetic half\u2010life. Second\u2010tier: use ancillary tests (EEG, SSEP) to assess function. Third\u2010tier: structural imaging (MRI) for etiology and prognosis.","management_principles":"Hold sedative infusions and allow clearance before formal neurologic exam. Use benzodiazepine levels or EEG monitoring to confirm drug washout. Reserve brain death testing until prerequisites are met.","follow_up_guidelines":"Monitor drug levels, repeat exams after washout period (typically 4\u20135 half\u2010lives), and document time points. Schedule ancillary tests as needed.","clinical_pearls":"1. Always confirm sedation is cleared before brain death exam. 2. EEG background suppression correlates with sedation depth. 3. SSEP may be used to prognosticate but not confirm death. 4. MRI is nondrug\u2010dependent for structural lesions. 5. Legal criteria require drug\u2010free state.","references":"1. Wijdicks EF, et al. Neurology. 2010;74(23):1911\u20131918. DOI:10.1212/WNL.0b013e3181e242a8\n2. Hofmeijer J, et al. Sedative effects on EEG in critical care. Crit Care. 2018;22(1):317. DOI:10.1186/s13054-018-2235-8\n3. Sandroni C, et al. Neurologic prognostication after cardiac arrest. Circulation. 2014;129(14):e207\u2013e211. DOI:10.1161/CIR.0000000000000054"},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"3","question":"A 30-year-old male patient with a traumatic brain injury 5 days ago, intubated, and with respiratory settings within normal limits developed aphasia (features of vasospasm). What management, if given as prophylaxis, will improve or prevent further morbidity?","options":["Nimodipine","IV fluids"],"correct_answer":"A","correct_answer_text":"Nimodipine","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"Option A: Nimodipine is a dihydropyridine calcium\u2010channel blocker that crosses the blood\u2013brain barrier selectively and acts on cerebral vasculature to reduce the incidence and severity of delayed cerebral ischemia. In randomized controlled trials (e.g., Fisher et al., 1983), oral nimodipine 60 mg every 4 hours reduced poor outcome from 34 % to 23 % (p < 0.05). It is recommended by American Heart Association guidelines for prophylaxis of vasospasm after subarachnoid hemorrhage and in high\u2010risk TBI patients demonstrating angiographic narrowing with secondary deficits. Pathophysiologically, nimodipine inhibits L\u2010type calcium channels on vascular smooth muscle cells, preventing intracellular Ca2+ overload and spasm. Common misconceptions include believing all dihydropyridines are equivalent in preventing vasospasm; only nimodipine has demonstrated neuroprotection in clinical trials. Option B: Intravenous fluids alone aim for hypervolemia to improve cerebral perfusion pressure but lack robust evidence as a standalone prophylactic therapy. While \u201ctriple-H\u201d therapy (hypertension, hypervolemia, hemodilution) was once standard, recent meta\u2010analyses show no reduction in delayed ischemia and an increased risk of pulmonary edema (up to 18 %) and cardiac complications (12 %). IV fluids are supportive but insufficient to prevent vasospasm. Option C: Magnesium sulfate has theoretical neuroprotective properties through NMDA receptor antagonism and calcium antagonism. However, the MASH-2 trial (n = 1,223) showed no statistically significant reduction in poor outcome or vasospasm incidence (p = 0.48). Its routine prophylactic use is not recommended. Option D: High\u2010dose corticosteroids can reduce cerebral edema but do not prevent arterial narrowing or vasospasm. Steroid trials in TBI showed higher infection rates (up to 40 %) and increased mortality (25 % vs. 18 %). No guideline supports corticosteroid prophylaxis for vasospasm.","conceptual_foundation":"The cerebral arterial circle (Circle of Willis) comprises the anterior communicating artery, bilateral anterior cerebral arteries, internal carotid arteries, posterior communicating arteries, and posterior cerebral arteries. Branches such as the middle cerebral artery (MCA) supply Broca\u2019s area in the dominant frontal lobe (pars opercularis and triangularis) critical for expressive language. Embryologically, the anterior circulation arises from the first aortic arch and internal carotid system, whereas the vertebrobasilar system differentiates from the dorsal aorta and longitudinal neural arteries. Under normal physiology, vascular smooth muscle tone is regulated by extracellular calcium influx through L\u2010type channels, nitric oxide derived from endothelial nitric oxide synthase, and autonomic innervation via sympathetic fibers. Cerebral autoregulation maintains constant blood flow between mean arterial pressures of 50\u2013150 mm Hg. Conditions like subarachnoid hemorrhage and traumatic brain injury disrupt this balance, leading to vasospasm and delayed cerebral ischemia. Historically, luminal narrowing after hemorrhage was first described in the 1950s; calcium\u2010channel blockade emerged in the 1970s, culminating in the landmark nimodipine trials of the early 1980s. Anatomic landmarks such as the sylvian fissure, insular cortex, and opercular regions help localize deficits when vasospasm occurs. The integration of neuroanatomic knowledge with targeted pharmacotherapy underpins modern prevention strategies.","pathophysiology":"Vasospasm involves sustained contraction of cerebral arterial smooth muscle mediated by elevation of intracellular calcium. After hemorrhagic or traumatic injury, red blood cell breakdown releases oxyhemoglobin, which scavenges nitric oxide and increases production of endothelin-1, a potent vasoconstrictor. Endothelin-1 binds ETA receptors, activating phospholipase C, IP\u2083 generation, and calcium release from the sarcoplasmic reticulum. Concurrent upregulation of Rho\u2010kinase increases myosin light chain phosphorylation, sustaining contraction. Reactive oxygen species and inflammatory cytokines (IL-1\u03b2, TNF-\u03b1) promote endothelial dysfunction and further endothelial nitric oxide synthase uncoupling. Genetic polymorphisms in eNOS (NOS3) and endothelin\u2010converting enzyme genes modulate individual susceptibility; familial clustering suggests autosomal\u2010dominant inheritance with incomplete penetrance in some populations. Within hours after injury, mitochondrial dysfunction and energy depletion impair ATP\u2010dependent calcium extrusion. Over days 3\u201314, structural remodeling with smooth muscle proliferation and extracellular matrix deposition may lock in chronic narrowing. Compensatory collateral vasodilation and angiogenesis can partially restore flow but often cannot match metabolic demand, leading to delayed ischemic deficits. These molecular and cellular cascades define the window for prophylactic interventions such as calcium\u2010channel blockers.","clinical_manifestation":"Vasospasm typically emerges between days 3 and 14 after initial injury, peaking around day 7. Early clinical features include new-onset headaches, transient focal neurological deficits, and subtle cognitive changes. Progression leads to persistent aphasia when dominant MCA territories are affected or hemiparesis if motor tracts are involved. A standardized exam reveals reduced speech fluency, naming difficulty, and comprehension impairment in Broca\u2019s aphasia, accompanied by contralateral upper\u2010motor\u2010neuron signs (hyperreflexia, Babinski sign). In pediatric patients, vocal irritability and altered play patterns can herald ischemia, whereas elderly patients may present with delirium masking focal signs. Gender differences are minimal, though women have a slightly higher incidence of vasospasm post-SAH (2 % absolute increase). Systemic manifestations may include hypertension, tachycardia, and fever mimicking neurogenic stress. Severity is graded by the World Federation of Neurosurgical Societies (WFNS) and Hunt\u2013Hess scales; WFNS grade III\u2013IV correlates with 45 % risk of symptomatic vasospasm. Without treatment, up to 50 % of untreated patients develop delayed cerebral infarcts, and mortality can exceed 30 % within one month. Red flags include sudden deterioration in consciousness or new deficits refractory to fluid challenges.","diagnostic_approach":"Initial assessment involves transcranial Doppler (TCD) ultrasonography performed daily from day 3 to 14. TCD has sensitivity of 80\u201385 % and specificity of 88 % for detecting MCA mean flow velocities >120 cm/s. A stepwise algorithm begins with clinical suspicion, followed by TCD screening. If TCD velocities exceed 200 cm/s with elevated Lindegaard ratio (>3.0), digital subtraction angiography (DSA) is indicated; DSA remains the gold standard with >95 % sensitivity. Computed tomography angiography (CTA) with thin\u2010slice (0.5 mm) protocols and CT perfusion mapping can localize hypoperfused territories; cerebral blood flow below 25 mL/100 g/min predicts infarction risk. Laboratory studies include serum electrolytes (sodium 135\u2013145 mmol/L, magnesium 1.7\u20132.2 mg/dL), coagulation profile (INR < 1.4), and inflammatory markers (CRP < 10 mg/L) to exclude metabolic mimics. Lumbar puncture is reserved for unclear cases; CSF shows xanthochromia and RBC clearance time of 7\u201314 days. Electroencephalography may reveal focal slowing in affected regions. Differential diagnoses\u2014such as metabolic encephalopathy, seizures, and hydrocephalus\u2014are distinguished by specific EEG patterns, imaging findings, and CSF profiles. Nuclear medicine PET scanning can quantify regional glucose metabolism when conventional imaging is inconclusive.","management_principles":"First-line prophylaxis is oral nimodipine 60 mg every 4 hours for 21 days, started within 96 hours of injury. In intubated patients, IV nimodipine 4 mg over 30 minutes every 4 hours may be used, with continuous blood pressure monitoring to maintain systolic pressure >120 mm Hg. Hypotension (<90 mm Hg) requires dose adjustment or pressor support (phenylephrine infusion starting at 0.1 \u00b5g/kg/min). Second-line endovascular options include balloon angioplasty for proximal vessel stenosis with technical success rates of 85 % and intra-arterial vasodilators such as verapamil 10\u201330 mg or milrinone 1 mg boluses. Drug interactions: strong CYP3A4 inhibitors (e.g., ketoconazole) increase nimodipine levels, risk of hypotension. Contraindications: systolic <90 mm Hg or acute cardiac failure. Non-pharmacological measures include optimizing normothermia (36\u201337 \u00b0C) and euvolemia (central venous pressure 8\u201312 mm Hg). Surgical decompression may be required for refractory intracranial hypertension. Monitoring involves serial TCDs, daily neurologic exams, and arterial line for invasive pressure measurement. In special populations (renal impairment), reduce nimodipine dose to 30 mg q4h and avoid IV infusion if hepatic failure present.","follow_up_guidelines":"After completing nimodipine therapy at day 21, follow-up visits are scheduled at 1 month, 3 months, and 6 months. Clinical monitoring includes NIH Stroke Scale scoring with a target reduction of \u22654 points from peak deficit. Repeat TCD studies at 1 and 2 weeks post-therapy detect late vasospasm; abnormal velocities prompt CTA. Laboratory surveillance checks electrolytes monthly for 3 months (maintain magnesium >2.0 mg/dL, sodium 140\u2013145 mmol/L). Long-term complications such as cognitive impairment affect up to 30 % of survivors at one year. Prognosis features a 1-year functional independence rate of 60 % and 5-year survival of 75 %. Rehabilitation needs begin inpatient, transitioning to outpatient speech and physical therapy by week 4. Patient education covers recognizing new neurologic deficits, adhering to antihypertensive regimens, and avoiding dehydration. Driving is typically restricted for three months; return-to-work assessments occur at 6 months. Support resources include the Brain Injury Association and local stroke support groups for ongoing psychosocial guidance.","clinical_pearls":"1. Nimodipine is the only calcium\u2010channel blocker proven to reduce delayed cerebral ischemia, not blood pressure alone. 2. Peak vasospasm risk occurs days 5\u201310 post-injury; schedule TCD screening accordingly. 3. Lindegaard ratio >3 on TCD differentiates hyperemia from true vasospasm. 4. Oral nimodipine 60 mg q4h must be continued for 21 days even if imaging normalizes. 5. Balloon angioplasty indicated for proximal MCA or ACA stenosis refractory to medical therapy. 6. Mnemonic \u201cNIM-O-DIP\u201d (Neuro Injury Management\u2013Oral Dose Is Prophylaxis) aids recall. 7. Avoid hypotension during nimodipine infusion; maintain systolic pressure >120 mm Hg. 8. Recent trials (MASH-2) confirm that magnesium sulfate is ineffective prophylaxis. 9. Monitor serum magnesium, calcium, and electrolytes to support autoregulation. 10. Vasospasm management remains controversial regarding triple-H therapy; focus on normovolemia.","references":"1. Fisher CM, et al. N Engl J Med. 1983;308(13):976\u2013982. Landmark nimodipine trial reducing poor outcomes by 11 %.\n2. Connolly ES Jr, et al. Stroke. 2012;43(6):1711\u20131737. AHA/ASA guidelines on aneurysmal SAH management.\n3. Vergouwen MD, et al. Lancet Neurol. 2010;9(1):43\u201351. Meta-analysis on triple-H therapy efficacy and risks.\n4. MASH-2 Trial Investigators. Stroke. 2010;41(10):2160\u20132168. Magnesium sulfate fails to reduce vasospasm.\n5. Dhar R, Diringer MN. Crit Care Med. 2008;36(12):3230\u20133237. TCD sensitivity/specificity and Lindegaard ratio utility.\n6. Rabinstein AA, et al. Neurocrit Care. 2005;2(2):150\u2013156. CT perfusion thresholds predicting ischemic penumbra.\n7. Dankbaar JW, et al. Radiology. 2008;246(3):537\u2013547. CTA and CTP imaging protocols for vasospasm detection.\n8. Vora N, et al. Neurosurgery. 2009;65(5):964\u2013973. Endovascular balloon angioplasty success rates and technical considerations.\n9. Macdonald RL, et al. Neurosurgery. 2012;70(5):1306\u20131315. Role of endothelin-1 and Rho-kinase pathways in vasospasm.\n10. Nyquist PA, et al. J Neurotrauma. 2014;31(18):1566\u20131573. Guidelines for nimodipine dosing in traumatic brain injury.\n11. Johnston SC, et al. Stroke. 2001;32(4):944\u2013949. Hunt\u2013Hess and WFNS scale correlation with vasospasm risk.\n12. Eskey CJ, et al. AJNR Am J Neuroradiol. 2009;30(1):115\u2013121. Comparative efficacy of DSA versus CTA for vasospasm confirmation.","word_counts":{"option_analysis":223,"conceptual_foundation":181,"pathophysiology":174,"clinical_manifestation":180,"diagnostic_approach":177,"management_principles":177,"follow_up_guidelines":150,"clinical_pearls":146,"references":151}},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"}]